There are currently 700 clinical trials in San Diego, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California, San Diego, Rady Children's Hospital - San Diego, GSK Investigational Site and Naval Medical Center - San Diego. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04628767
Recruiting
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: UC San Diego Medical Center - Hillcrest, San Diego, California
Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228
Recruiting
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Pa0016 50663, San Diego, California
Conditions: Psoriatic Arthritis
Register for Updates
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Recruiting
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Research Site, San Diego, California
Conditions: Immunoglobulin A Nephropathy, IgAN
Register for Updates
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
NCT06465186
Recruiting
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well peopl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/03/2025
Locations: Acclaim Clinical Research ( Site 0137), San Diego, California
Conditions: Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
Register for Updates
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
NCT05687110
Recruiting
This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has become damaged as cells grow and divide. Cancer cells that cannot repair their damaged DNA die. This medication may help shrink or stabilize cancer with a mutation in DNA repair genes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: UC San Diego Medical Center - Hillcrest, San Diego, California
Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
ALTERRA Post-Approval Study
NCT05378386
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
ALL
Ages:
All
Trial Updated:
07/03/2025
Locations: Rady's Children's Hospital, San Diego, California
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
07/03/2025
Locations: Research Site, San Diego, California +1 locations
Conditions: Asthma
Register for Updates
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/03/2025
Locations: Research Site, San Diego, California
Conditions: Heart Failure and Impaired Kidney Function
Register for Updates
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276
Recruiting
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-expres... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: UC San Diego Medical Center - Hillcrest, San Diego, California
Conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Register for Updates
Screening Study for Participants With Malignant Tumors
NCT05419375
Recruiting
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Southern California Kaiser Permanente, San Diego, California
Conditions: Solid Tumors
Register for Updates
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
NCT06088199
Recruiting
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/02/2025
Locations: MedDerm Associates, San Diego, California
Conditions: Plaque Psoriasis
Register for Updates
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
NCT06568172
Recruiting
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses hig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: UC San Diego Medical Center - Hillcrest, San Diego, California
Conditions: Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Resectable Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Register for Updates